Genetic predisposition of responsiveness to therapy for chronic hepatitis C

Pharmacogenomics

Volumn 7, Issue 5, 2006, Pages 697-709

  Hwang, Yuchi ^a   Chen, Elison Y ^a   Gu, Z John ^a   Chuang, Wan Long ^b   Yu, Ming Lung ^b   Lai, Ming Yang ^c   Chao, You Chen ^d   Lee, Chuan Mo ^e   Wang, Jing Houng ^e   Dai, Chia Yen ^b,f   Bey, Monica Shian Jy ^a   Liao, Ya Tang ^a   Chen, Pei Jer ^c   Chen, Ding Shinn ^c  

^a VITA GENOMICS INC   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^e CHANG GUNG UNIVERSITY   (Taiwan)

^f KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

Author keywords

HCV; IFN ; Pharmacogenomics; Prediction model; SNP

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER B; ADENOSINE DEAMINASE; ALPHA INTERFERON; CARRIER PROTEIN; CASPASE 5; CYSTEINE PROTEINASE; DNA; FIBROBLAST GROWTH FACTOR 1; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN 1; INTERFERON INDUCED PROTEIN 44; PEGINTERFERON; PROTEIN DERIVATIVE; RECEPTOR PROTEIN; RIBAVIRIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR ASSOCIATED PROTEIN 1; UNCLASSIFIED DRUG;

ADULT; AGED; ALGORITHM; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG CHOICE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEPATITIS C; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; PHARMACOGENOMICS; PREDICTION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; TAIWAN; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 84984550485     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.7.5.697     Document Type: Article

References (38)

1. Alberti A, Benvegnu L: Management of hepatitis C. J. Hepatol. 38(Suppl. 1), S104-S118 (2003).
2. Lai MY, Kao JH, Yang PM et al.: Long-term efficacy of ribavirin plus interferon α in the treatment of chronic hepatitis C. Gastroenterology 111, 1307-1312 (1996).
3. Lauer GM, Walker BD: Hepatitis C virus infection. N. Engl. J. Med. 345, 41-52 (2001).
4. Manns MP, McHutchison JG, Gordon SC et al.: Peginterferon α2b plus ribavirin compared with interferon α2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358, 958-965 (2001).
5. Fried MW, Shiffman ML, Reddy KR et al.: Peginterferon α2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347, 975-982 (2002).
6. Bacon BR: Managing hepatitis C. Am. J. Manag. Car. 10(2 Suppl.), S30-S40 (2004).
7. Hwang Y, Su C, Chen DS, Chen PJ: Prospect of individualized medicine in chronic hepatitis C therapy by pharmacogenomics. Current Pharmacogenomics 4, 157-167 (2006).
8. Fried MW: Viral factors affecting the outcome of therapy for chronic hepatitis C. Rev. Gastroenterol. Disord. 4(Suppl. 1), S8-S13 (2004).
9. Bruno R, Sacchi P, Maiocchi L, Zocchetti C, Filice G: Host factors affecting the outcome of treatment of hepatitis C. Rev. Gastroenterol. Disord. 4(Suppl. 1), S3-S7 (2004).
10. Tang J, Kaslow RA: Pharmacogenomic perspectives of chronic hepatitis C virus (HCV) infection. Pharmacogenomics J 4, 171-174 (2004).
11. Suzuki F, Arase Y, Suzuki Y et al.: Single nucleotide polymorphism of the MXA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. J. Viral Hepat. 11, 271-276 (2004).
12. Hijikata M, Ohta Y, Mishiro S: Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt -88) correlated with the response of hepatitis C patients to interferon. Intervirology 43, 124-127 (2004).
13. Yee LJ, Tang J, Gibson AW, Kimberly R, Van Leeuwen DJ, Kaslow RA: Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 33, 708-712 (2001).
14. Andrade Jr DR, Andrade DR: The influence of the human genome on chronic viral hepatitis outcome. Rev. Inst. Med. Trop. Sao Paulo 46, 119-126 (2004).
15. Hwang Y, Chen KD, Chang CW, Chen JL: SNP genotype modeling - pharmacogenomic approach for studying hepatitis C treatment. International Liver Congress, Hong Kong, p 96-97 (2004).
16. Kessler HH, Santner B, Umlauft F et al.: Detection of hepatitis C viral sequences in serum by 'nested' polymerase chain reaction (PCR) and a commercial single-round PCR assay. Clin. Diagn. Virol. 4, 239-250 (1995).
17. Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68, 978-989 (2001).
18. Zheng B, Agresti A: Summarizing the predictive power of a generalized linear model. Stat. Med. 19, 1771-1781 (2000).
19. Hoofnagle JH: Management of hepatitis C: current and future perspectives. J. Hepatol. 31(Suppl. 1), 264-268 (1999).
20. Chen L, Borozan I, Feld J. et al.: Hepatic gene expression discriminates responders and non-responders in treatment of chronic hepatitis C viral infection. Gastroenterology 128, 1437-1444 (2005).
21. Jayan GC, Casey JL: Increased RNA editing and inhibition of hepatitis Δ virus replication by high-level expression of ADAR1 and ADAR2. J. Virol. 76, 3819-3827 (2002).
22. Thornton AM, Buller RM, DeVico AL, Wang IM, Ozato K: Inhibition of human immunodeficiency virus type 1 and vaccinia virus infection by a dominant negative factor of the interferon regulatory factor family expressed in monocytic cells. Proc. Natl Acad. Sci. USA 93, 383-387 (1996).
23. Weisz A, Marx P, Sharf R et al.: Human interferon consensus sequence binding protein is a negative regulator of enhancer elements common to interferon-inducible genes. J. Biol. Chem. 267, 25589-25596 (1999).
24. Kitamura A, Takahashi K, Okajima A, Kitamura N: Induction of the human gene for p44, a hepatitis C-associated microtubular aggregate protein, by interferon-α/β. Eur. J. Biochem. 224, 877-883 (1994).
25. Airoldi A, Zavaglia C, Silini E et al.: Lack of a strong association between HLA class II, tumour necrosis factor and transporter associated with antigen processing gene polymorphisms and virological response to α-interferon treatment in patients with chronic hepatitis C. Eur. J. Immunogenet. 31, 259-265 (2004).
26. Sugimoto Y, Kuzushita N, Takehara T et al.: A single nucleotide polymorphism of the low molecular mass polypeptide seven gene influences the interferon response in patients with chronic hepatitis C. J. Viral Hepat. 9, 377-384 (2002).
27. Kuzushita N, Sugimoto Y, Sasaki Y, Hayashi N: Involvement of TAP2 and LMP7 gene polymorphisms in HCV infection. Nippon Rinsho 59, 1248-1253 (2001).
28. Ulloa L, Doody J, Massague J: Inhibition of TGFβ/SMAD signal transduction by the interferon-γ/STAT pathway. Nature 397, 710-713 (1999).
29. Kretzschmar M, Doody J, Massague J: Opposing BMP and EGF signaling pathways converge on the TGF-β family mediator Smad1. Nature 389, 618-622 (1997).
30. Wurthner JU, Frank DB, Felici A et al.: Transforming growth factor-β receptor-associated protein 1 is a Smad4 chaperone. J. Biol. Chem. 276, 19495-19502 (2001).
31. Caronia S, McGarvey MJ, Goldin RD, Foster GR: Negative correlation between intrahepatic expression of hepatitis C antigens and apoptosis despite high-level expression of Fas and HLA antigens. J. Viral Hepat. 11, 511-518 (2004).
32. Zhu LX, Liu J, Xie YH et al.: Expression of hepatitis C virus envelope protein 2 induces apoptosis in cultured mammalian cells. World J. Gastroenterol. 10, 2972-2978 (2004).
33. Prikhod'ko EA, Prikhod'ko GG, Siegel RM, Thompson P, Major ME, Cohen JI: The NS3 protein of hepatitis C virus induces caspase-8-mediated apoptosis independent of its protease or helicase activities. Virology 329, 53-67 (2004).
34. Munday NA, Vaillancourt JP, Ali A et al.: Molecular cloning and pro-apoptotic activity of ICErelII and ICErelIII, members of the ICE/ CED-3 family of cysteine proteases. J. Biol. Chem. 270, 15870-15876 (1995).
35. Faucheu C, Blanchet AM, Collard-Dutilleul V, Lalanne JL, Diu-Hercend A: Identification of a cysteine protease closely related to interleukin-1 β-converting enzyme. Eur. J. Biochem. 236, 207-213 (1996).
36. Jin-no K, Tanimizu M, Hyodo I, Kurimoto F, Yamashita T: Plasma level of basic fibroblast growth factor increases with progression of chronic liver disease. J. Gastroenterol. 32, 119-121 (1997).
37. Jung J, Zheng M, Goldfarb M, Zaret KS: Initiation of mammalian liver development from endoderm by fibroblast growth factors. Science 284, 1998-2003 (1999).
38. Jensen DM, Morgan TR, Marcellin P et al.: Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ ribavirin therapy. Hepatology 43, 954-960 (2006).